Half-dose depot triptorelin comparable to reduced daily buserelin: a randomized clinical trial

Pituitary suppression by depot GnRH agonist may be excessive for ovarian stimulation. This study compares the efficacy of a single half-dose depot triptorelin and reduced-dose daily buserelin in a long protocol ICSI/ET. A total of 182 patients were randomized into two groups using sealed envelopes. Pituitary desensitization was obtained in group 1 [91 patients] with half-dose [1.87 mg] depot triptorelin in the mid-luteal phase of their menstrual cycle, and in group 2 [91 patients] with standard daily dose [0.5 mg] buserelin, which was then reduced to 0.25 mg at the start of human menopausal gonadotropin [HMG] stimulation. No significant differences were found among those who received HCG in terms of clinical pregnancy rate [34.4% in both groups], implantation rate [14.8% in group 1 versus 11.1% in group 2], fertilization rate [93.3 versus 95.6%], poor response rate [11.1 versus 6.7%], and miscarriage rate [11.1 versus 7.8%]. No significant differences were seen in number of HMG ampoules used, follicles at HCG administration, and oocytes retrieved. The number of days of stimulation was significantly reduced in group 2 [11.2 +/- 1.8 in group 1 versus 10.6 +/- 1.9, P = 0.030]. A half-dose of depot triptorelin can be successfully used in ovarian stimulation instead of reduced-dose daily buserelin, with more patient comfort and reduced stress and cost of injections

Determinig the relation between non-fasting serum leptin- BMI ratio and follicular fluid leptin to ART outcomes

Considering the economical and psychological burden of assisted reproductive technologies [ART], finding factors predicting ART results is of great value. So this study was undertaken to evaluate whether serum and follicular and serum leptin to body mass index [BMI] are predictive of ART outcomes. 99 non-polycystic ovary patients from the body of patients referring to infertility ward of Shariati Hospital, from April to September 2005, were selected and underwent the long protocol of GnRH agonist ovarian hyperstimulation. Serum leptin was measured on the 3rd day of menstrual cycle. Follicular fluid [FF] was collected on the day of oocyte retrieval. The serum and follicular fluid leptin levels were determined by ELISA. Mean the levels of serum and follicular fluid leptin and leptin to BMI ratios were compared in pregnant and nonpregnant women, using SPSS software, student t-test. P-values <0.05 were considered significant. Geometrical mean serum leptin [16.42 +/- 1.48ng/ml for the nonpregnant and 14.09 +/- 2.20 ng/ml for the pregnant cases], follicular fluid leptin [8.73 +/- 2.56ng/ml for the nonpregnant and 11.072.76ng/ml for the pregnant cases] and serum leptin to BMI ratios [0.64 +/- 1.61 for the nonpregnant and 0.55 +/- 2.04 for the pregnant cases] were not significantly different. According to the results, serum and follicular leptin levels and serum leptin to BMI ratios are not predictive of ART outcomes and in the meantime they should not be considered as a prognostic factor but further studies are recommended with more selective criteria to address infertility causes

[Evaluation of factors influencing GIFT and comparison of GIFT and IVF results at infertility center of Shariati hospital during 1376-78]

Today there are a number of methods of Assisted Reproductive Technology. The classic method of IVF has a pregnancy rate of 11-12%. GIFT is a new method with a pregnancy rate of 25-35%. In this study 71 patients were included in GIFT cycle. In our study Pregnancy rate of GIFT was 29.6% whereas in 130 cycles of IVF the pregnancy rate was 14.6%. In this study we found that female age, the number of transfered oocytes, serum estradiol on hCG injection day and sperm characteristics were influential factors affecting the outcome of GIFT